XIAP and diabetes mellitus: These findings underscore the unique properties of ILP-Ap04, which not only expand our understanding of venom-derived peptides, but also open new avenues for therapeutic innovation, highlighting the potential of sea anemone venom insulin as a template for novel drug design in diabetes management.